Association of CD34+ Cell Dose with Progression-free Survival after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation in Children with Hematologic Malignancies.

Abstract

BACKGROUND:

A higher CD34+ cell dose is associated with improved engraftment but may also be associated with an increased risk of complications after allogeneic hematopoietic stem cell transplantation, including graft-versus-host disease (GVHD).

METHODS:

We retrospectively analyze the impact of CD34+ cell dose on OS, PFS, neutrophil engraftment, platelet engraftment, treatment-related mortality, and GVHD grading.

RESULTS:

For analyses, CD34+ cell dose was stratified into low (< 8.5 × 106/kg) and high (> 8.5 × 106/kg). A subgroup analysis of higher CD34+ cell dose leads to prolonged OS and PFS, but statistical significance was achieved only for PFS (OR 0.36; 95%CI 0.14-0.95; P = 0.04).

CONCLUSIONS:

This study reinforced that CD34+ cell dose at the time of allo-HSCT retained a positive impact on PFS.

• Authors: Yi-Lun Wang, Tsung-Yen Chang, Hsin-Yi Hsieh, Shih-Hsiang Chen, Yu-Chuan Wen, Chia-Chi Chiu, Tang-Her Jaing
• Journal: Transplantation proceedings (Transplant Proc) Vol. 55 Issue 2 Pg. 481-484 (Mar 2023) ISSN: 1873-2623 [Electronic] United States
• PMID: 36863969 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 Elsevier Inc. All rights reserved.

Chemical References

• Antigens, CD34

Topics

• Humans
• Child
• Progression-Free Survival
• Retrospective Studies
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Hematologic Neoplasms (therapy)
• Graft vs Host Disease (etiology)
• Antigens, CD34 (analysis)